Novartis reported high uptake in its first large-scale public Bexsero vaccination program. The campaign was conducted in Quebec’s Saguenay-Lac-Saint-Jean region where the vaccine was offered to everyone aged 2 months through 20 years old.
Pfizer announced that it has signed into a definitive agreement to acquire two of Baxter’s marketed vaccines for $636 million. Pfizer will also acquire part of the vaccines’ production facilities in Orth, Austria.
A report from the Decision Resources Group gives the gold medal to Amgen’s evolocumab in the race among statin add-on therapies for dyslipidemia in its report Dyslipidemia (in statin-treated patients): Do Physicians Have High Hopes for LDL-lowering Therapies in Cardiovascular Outcomes?
Allergies specialist global healthcare company Stallergenes announced that it has completed an acquisition of the entire share capital of Argentinean allergen immunotherapy (AIT) firm, Alergo Pharma. No financial terms of the agreement were disclosed by either company.
Bristol-Myers Squibb and Ono Pharmaceuticals announced that the companies have entered an agreement to develop and market Opdivo (nivolumab), Yervoy (ipilimumab), and three other drugs in South East Asia. Ono originally held exclusive rights to nivolumab in the three countries while BMS retained rights in the rest of its territories. The new agreement provides BMS access to Opdivo in the three countries. BMS also held global rights to Yervoy and the three other drugs, namely lirilumab, urelumab, and BMS-986016.
The Medical Research Council (MRC) has partnered with seven global big pharma firms to search new uses for deprioritized pharmaceutical compounds. These are AstraZeneca, Eli Lilly & Co., GlaxoSmithKline, Janssen R&D, Pfizer, Takeda, and UCB.